EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Serum miRNA Signatures in Cancer Cachexia Depend on Systemic Inflammation

Terese Louise Schmidberger Karlsen, Robin Mjelle, Ola Magne Vagnildhaug iD, Trude Rakel Balstad iD, Are Korsnes Kristensen, Jens Erik Slagsvold, Ganna S Westwik, Hege Elvebakken, Eva Hofsli, Ingunn Hatlevoll, Tora Skeidsvoll Solheim iD

Current Oncology · 06.11.2025 · 32 (11) · 620

DOI: 10.3390/curroncol32110620 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Current Oncology, online erschienen am 06.11.2025. Verfasst von Terese Louise Schmidberger Karlsen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Clinic, St. Olavs Hospital, 7030 Trondheim, Norway. Hauptthemen laut MEDLINE: Cachexia, Inflammation, MicroRNAs, Colorectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Joint Research Council at St. Olavs Hospital HF - Trondheim University Hospital and the Faculty of Medicine, Norwegian University of Science and Technology…, Joint Research Council at St. Olavs Hospital HF—Trondheim University Hospital, Faculty of Medicine, Norwegian University of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cachexia is a complex syndrome marked by involuntary weight and muscle loss, often driven by systemic inflammation. This multicenter, longitudinal observational study investigated circulating microRNA (miRNA) profiles in patients with unresectable locally advanced or metastatic colorectal cancer, comparing those with and without cachexia and inflammation. A total of 168 patients were categorized into four groups based on cachexia and C-reactive protein (CRP) levels. Cachexia was defined using the 2011 consensus criteria, incorporating weight loss, low BMI, and sarcopenia. Patients with both cachexia and systemic inflammation exhibited significantly distinct miRNA profiles as well as poorer overall survival (HR 2.10, p < 0.001) compared to patients with neither condition. No significant differences were observed in patients lacking either cachexia or inflammation or both. Inflammatory cachexia emerged as a biologically distinct entity, with 82 differentially expressed miRNAs. The miR-320-family, miR-6087, miR-4488, miR-29a-3p, miR-194-5p, and miR-10a-5p were most altered, several of which are linked to muscle mass, metabolism, lipid, and protein synthesis. These findings highlight the pivotal role of systemic inflammation in cancer cachexia and support its inclusion in diagnostic criteria. Moreover, circulating miRNAs may serve as promising biomarkers for identifying cachexia in cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaInflammationMicroRNAsColorectal NeoplasmsNeoplasmsHumansMaleFemaleMiddle AgedAgedLongitudinal Studies

Stichwörter der Autor:innen

MiRNAbiomarkerscachexiacancercolorectal cancerinflammation

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Cancer Clinic, St. Olavs Hospital, 7030 Trondheim, Norway.
  • Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU-Norwegian University of Science and Technology, 7491 Trondheim, Norway.
  • Department of Clinical Medicine, Clinical Nutrition Research Group, UiT The Arctic University of Norway, 9019 Tromsø, Norway.
  • Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health Trust, 7601 Levanger, Norway.
  • Department of Oncology, Møre & Romsdal Hospital Trust, 6017 Ålesund, Norway.

ORCID-Profile: Ola Magne Vagnildhaug, Trude Rakel Balstad, Tora Skeidsvoll Solheim

Förderung

  • The Joint Research Council at St. Olavs Hospital HF - Trondheim University Hospital and the Faculty of Medicine, Norwegian University of Science and Technology…
  • Joint Research Council at St. Olavs Hospital HF—Trondheim University Hospital
  • Faculty of Medicine, Norwegian University of Science and Technology
  • Liaison Committee for Education, Research and Innovation in Central Norway

Zitieren

APA

Karlsen, T. L. S., Mjelle, R., Vagnildhaug, O. M., Balstad, T. R., Kristensen, A. K., Slagsvold, J. E., Westwik, G. S., Elvebakken, H., Hofsli, E., Hatlevoll, I., & Solheim, T. S. (2025). Serum miRNA Signatures in Cancer Cachexia Depend on Systemic Inflammation. Current Oncology, 32(11), 620. https://doi.org/10.3390/curroncol32110620

Vancouver

Karlsen TLS, Mjelle R, Vagnildhaug OM, Balstad TR, Kristensen AK, Slagsvold JE, et al. Serum miRNA Signatures in Cancer Cachexia Depend on Systemic Inflammation. Current Oncology. 2025;32(11):620. doi:10.3390/curroncol32110620

BibTeX
@article{Karlsen2025,
  author = {Karlsen, Terese Louise Schmidberger and Mjelle, Robin and Vagnildhaug, Ola Magne and Balstad, Trude Rakel and Kristensen, Are Korsnes and Slagsvold, Jens Erik and Westwik, Ganna S and Elvebakken, Hege and Hofsli, Eva and Hatlevoll, Ingunn and Solheim, Tora Skeidsvoll},
  title = {Serum miRNA Signatures in Cancer Cachexia Depend on Systemic Inflammation},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {11},
  pages = {620},
  doi = {10.3390/curroncol32110620}
}
Kostenlos starten →